Primary Membranous Nephropathy (PMN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Primary Membranous Nephropathy (PMN) Emerging Therapy and TPP Insights

Thelansis’s “Primary Membranous Nephropathy (PMN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Primary Membranous Nephropathy (PMN) Overview

Primary Membranous Nephropathy (PMN) is a specific, autoimmune-mediated glomerular disease that serves as one of the leading causes of nephrotic syndrome in non-diabetic adults. Clinically, it manifests with massive proteinuria (>3.5 g/day), profound peripheral edema, hypoalbuminemia, hyperlipidemia, and a significantly elevated risk of thromboembolic events, such as renal vein thrombosis. The pathophysiology is defined by the subepithelial deposition of IgG4 autoantibodies and complement complexes (specifically the C5b-9 membrane attack complex) on the glomerular basement membrane, which triggers severe podocyte injury and filtration barrier failure. In modern nephrology, PMN is classified by its distinct molecular drivers rather than just morphology; it is now recognized that 70–80% of these cases are driven by circulating autoantibodies against the M-type phospholipase A2 receptor (PLA2R), with another 1–5% targeting THSD7A. This molecular understanding has revolutionized clinical management, allowing for non-invasive diagnosis via serological testing in select patients and utilizing serial antibody titers to guide risk-stratified immunosuppression—most notably with B-cell depleting agents like rituximab—to induce immunological and subsequent clinical remission.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Primary Membranous Nephropathy (PMN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025